Country	NETHERLAND	USA		USA	Germany	
Company	Concept Medical	Abbott		Boston Scientific	Biotronik	
Product	Abluminus DES +	Xience V		Synergy	Orsiro	
Trial / Registry	en-ABL	SPIRIT Trials		The Evolve II study	BIOSCIENCE Trial	
Objective	To evaluate the safety and efficacy of the AbluminusDES+ in all-comers population with minimal exclusion criteria, Multicenter,prospective,all-comers on going registry performed in 31centers.	We compared the safety and efficacy of the XIENCE V everolimuseluting stent (EES) with the TAXUS Express paclitaxel-eluting stent (PES) among the large cohort of randomized diabetic patients enrolled in the SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) trial.		The EVOLVE II diabetes substudy is a prospective, multicentre study conducted as part of the EVOLVE II, randomised, controlled, singleblind, non-inferiority trial	Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents, BIOSCIENCE trial was an investigator-initiated, single-blind, multicentre, randomized, noninferiority trial comparing BP-SES versus DP-EES	
Total patients	2500	3687		466	2119	
Products	Abluminus DES +	Xience V	Taxus	Synergy	Orsiro	Xience Prime
Diabetic Cohort	855	786	399	466	257	229
Result @ 1yr follow - up	1 Year follow up	1 Year follow up		1 Year follow up	1 Year follow up	
MACE	3.80%	6.50%	7.10%	-		
Cardiac Death	1.40%	0.90%	0.30%	0.70%	3.40%	3.40%
TVR / TLR	1.90%	3.60%	4.90%	TVR :- 5.3% / TLR :- 4.4%	5.60%	5.60%
ST	0.80%	0.80%	1.33%	1.10%	4.00%	3.10%